MAUDE Adverse Event Report: MEDTRONIC HEART VALVES DIVISION MEDTRONIC TRANSCATHETER VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV

Model Number MDT-TRANS VALVE

Device Problems Perivalvular Leak (1457); Inadequacy of Device Shape and/or Size (1583); Patient Device Interaction Problem (4001); Central Regurgitation (4068)

Patient Problems Atrial Fibrillation (1729); Non specific EKG/ECG Changes (1817); Heart Block (4444); Heart Failure/Congestive Heart Failure (4446); Valvular Insufficiency/ Regurgitation (4449); Mitral Valve Insufficiency/ Regurgitation (4451); Tricuspid Valve Insufficiency/ Regurgitation (4453)

Event Date 06/15/2023

Event Type  Injury  

Manufacturer Narrative

Citation: togashi d, sasaki k, okuyama k, et al.Two-year outcomes of ventricular-demand leadless pacemaker therapy for heart block after transcatheter aortic valve replacement.J innov card rhythm manag.2023;14(6):5491-5498.Published 2023 jun 15.Doi:10.19102/ icrm.2023.14062 earliest date of publication used for date of event.Medtronic product referenced: ¿self-expandable evolut¿ valve¿ ¿ which may have included evolut r (product code npt, pma# p130021), evolut pro (product code npt, pma# p130021), and evolut pro+ (product code npt, pma# p130021).Earliest approved product used for product code and pma#.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product, no definitive conclusion can be made regarding the clinical observations.Select patient information cannot be included in regulatory report due to regional privacy regulations.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.

Event Description

Literature was reviewed regarding the outcomes of ventricular-demand leadless pacemaker therapy for heart block after transcatheter aortic valve replacement (tavr).Medtronic evolut (n = 13) and non-medtronic sapien (n = 26) transcatheter valve types were implanted in the study population.After tavr, all 39 patients included in the study underwent permanent pacemaker implantation for new high-grade (complete or advanced) atrioventricular block.The authors observed 12 deaths during the two-year follow-up.No evidence was presented to suggest that a medtronic valve or its function contributed to any of the deaths.Other adverse events consisted of mitral regurgitation development, tricuspid regurgitation development, reduced left ventricular ejection fraction, prosthesis-patient mismatch, paravalvular regurgitation (moderate to severe), rehospitalization for heart failure, and new atrial fibrillation.No additional adverse events related to tavr were noted.

• Brand Name: MEDTRONIC TRANSCATHETER VALVE
• Type of Device: AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV
• Manufacturer (Section D): MEDTRONIC HEART VALVES DIVISION; 1851 e deere ave; santa ana CA 92705
• Manufacturer (Section G): MEDTRONIC HEART VALVES DIVISION; 1851 e deere ave; santa ana CA 92705
• Manufacturer Contact: alison sweeney ; parkmore business park west; galway ; EI ; 091708096
• MDR Report Key: 18763775
• MDR Text Key: 336055142
• Report Number: 2025587-2024-01087
• Device Sequence Number: 1
• Product Code: NPT
• Combination Product (y/n): N
• Reporter Country Code: JA
• PMA/PMN Number: P130021
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Foreign,Literature
• Reporter Occupation: Physician
• Type of Report: Initial
• Report Date: 02/22/2024

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Date FDA Received: 02/22/2024
• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Model Number: MDT-TRANS VALVE
• Device Catalogue Number: MDT-TRANS VALVE
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Date Manufacturer Received: 01/31/2024
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Required Intervention; Hospitalization